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IMPORTANCE Molecular diagnosis is difficult to achieve in disease groups with a highly
heterogeneous genetic background, such as cerebellar ataxia (CA). In many patients,
candidate gene sequencing or focused resequencing arrays do not allow investigators to
reach a genetic conclusion.
OBJECTIVES To assess the efficacy of exome-targeted capture sequencing to detect
mutations in genes broadly linked to CA in a large cohort of undiagnosed patients and to
investigate their prevalence.
DESIGN, SETTING, AND PARTICIPANTS Three hundred nineteen index patients with CA and
without a history of dominant transmission were included in the this cohort study by the
Spastic Paraplegia and Ataxia Network. Centralized storage was in the DNA and cell bank of
the Brain and Spine Institute, Salpetriere Hospital, Paris, France. Patients were classified into
6 clinical groups, with the largest being those with spastic ataxia (ie, CA with pyramidal signs
[n = 100]). Sequencing was performed from January 1, 2014, through December 31, 2016.
Detected variants were classified as very probably or definitely causative, possibly causative,
or of unknown significance based on genetic evidence and genotype-phenotype
considerations.
MAIN OUTCOMES ANDMEASURES Identification of variants in genes broadly linked to CA,
classified in pathogenicity groups.
RESULTS The 319 included patients had equal sex distribution (160 female [50.2%] and 159
male patients [49.8%]; mean [SD] age at onset, 27.9 [18.6] years). The age at onset was
younger than 25 years for 131 of 298 patients (44.0%) with complete clinical information.
Consanguinity was present in 101 of 298 (33.9%). Very probable or definite diagnoses were
achieved for 72 patients (22.6%), with an additional 19 (6.0%) harboring possibly pathogenic
variants. Themost frequently mutated genes were SPG7 (n = 14), SACS (n = 8), SETX (n = 7),
SYNE1 (n = 6), and CACNA1A (n = 6). The highest diagnostic rate was obtained for patients
with an autosomal recessive CAwith oculomotor apraxia–like phenotype (6 of 17 [35.3%]) or
spastic ataxia (35 of 100 [35.0%]) and patients with onset before 25 years of age (41 of 131
[31.3%]). Peculiar phenotypes were reported for patients carrying KCND3 or ERCC5 variants.
CONCLUSIONS AND RELEVANCE Exome capture followed by targeted analysis allows the
molecular diagnosis in patients with highly heterogeneous mendelian disorders, such as CA,
without prior assumption of the inheritancemode or causative gene. Being commonly
available without specific design need, this procedure allows testing of a broader range of
genes, consequently describing less classic phenotype-genotype correlations, and post hoc
reanalysis of data as new genes are implicated in the disease.
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H ereditary cerebellar ataxias (CAs) are clinically andge-neticallyheterogeneous.All transmissionmodeshavebeen described. The cardinal cerebellar syndrome is
frequently part of a complex clinical spectrum with addi-
tional neurologic and/or extraneurologic symptoms.1
Themost frequentautosomal recessive (AR)CAsareFried-
reich ataxia, caused by GAA repeat expansions in intron 1 of
FXN (OMIM 606829),2 and ataxia-telangiectasia, caused by
loss-of-functionmutations inATM (OMIM607585).3Nonclas-
sic clinical pictures have been described for both.4,5 Autoso-
mal dominant (AD) CAs aremost often caused by CAG repeat
expansions inATXN1 (OMIM601556),ATXN2 (OMIM601517),
ATXN3 (OMIM 607047), CACNA1A (OMIM 601011), ATXN7
(OMIM 607640), TBP (OMIM 600075), or ATN1 (OMIM
607462).6Overall,mutations inmore than140geneshavebeen
described, involving pathways such as mitochondrial func-
tions, DNA repair, transcription and translation, ciliary struc-
ture, and lipid biosynthesis.1,7
Sangersequencingofcandidategenesorpanelapproaches8
often fails to lead to a diagnosis.1We aimed to evaluate the ef-
ficacy of exome-capture sequencing followed by targeted
analysis of genes broadly linked to CA9-12 to identify muta-
tions in 319 patientswith undiagnosed CA andwithout anAD
transmission history. To our knowledge, this CA cohort is the
largest studied.
Methods
Patient Recruitment and Clinical Evaluation
Three hundred nineteen index cases of CA were recruited
by the Spastic Paraplegia and Ataxia (SPATAX) network
(https://spatax.wordpress.com/) and examined using a
standardized form (https://spatax.files.wordpress.com/2013
/09/fichecliniquespatax-eurospa-2011.pdf). The sexes were
equally distributed. For the 210 patients with available
information, the national origin was mostly France (112
[53.3%]) andcontinentalEurope (39 [18.6%]).Weclassified the
298 caseswith full phenotypic information into the following
6 clinical groups: (1) pure ataxic phenotype (n = 62), (2)
additional spastic component (spastic ataxia) (n = 100), (3)
complex late-onset clinical picturewith extrapyramidal signs
(n = 30), (4) metabolic presentation with mitochondrial
features (sensorineural hearing loss, ptosis, ophthalmoplegia,
optic atrophy, axonal neuropathy, cardiomyopathy, short
stature, and/or diabetes type 1) or white matter changes
(n = 70), (5) sensoryataxia (n = 19), or (6) aCAwithoculomotor
apraxia (AOA)–likepresentation (n = 17) (Table). The remaining
21patientswereunclassified.Thepatients’ familial anamneses
includednoevidenceofADtransmission.Recessive inheritance
was considered to beplausible basedon consanguinity (101 of
298 [33.9%]) or family history consisting of at least 2 affected
siblings (59 of 298 [19.8%])with no case in other generations.
According to a classic nonsystematic clinical approach,
expansions ofFXN (80 patients) or ADCA genes (132 patients,
includingATXN1 in 129,ATXN2 in 129,ATXN3 in 130,CACNA1A
in 126,ATXN7 in 110,TBP in47, andATN1 in 102)andmutations
in various genes (eg, APTX [OMIM 606350], SETX [OMIM
608465], SPG7 [OMIM 602783], SACS [OMIM 604490], and
POLG [OMIM174763])were ruledoutwhen thephenotypewas
suggested by means of clinical presumption or biological
workup (ie, measurement of albumin, cholesterol, or
α-fetoprotein level). This study was approved by the Paris
Necker ethics committee. Written informed consent was
obtained in accordance with French ethics regulations.
Sequencing and Bioinformatics
Exome-enriched libraries were prepared with the rapid-
capture expanded exome kit (Nextera; Illumina) and se-
quenced on the manufacturer’s system (HiSeq 2000; Illu-
mina) (2 × 100–base pair paired-end reads). Sequence
alignment and variant calling were performed following the
Broad Institute’s Genome Analysis Toolkit (GATK)13-15 ver-
sion 3best practices. Sequence readswere aligned against the
reference human genome (UCSC hg19) using the Burrows-
Wheeler Alignment tool.16 The Picard software toolset (http:
//broadinstitute.github.io/picard/) was used to calculate
summary alignmentmetrics andmark duplicate reads. Local
realignments near indels, base-score recalibration, variant
calling, jointgenotyping,andvariantqualityscore recalibration
were performed using GATK.
Variants were annotated with Annovar17 (http://annovar
.openbioinformatics.org/) and sorted with SnpSift18 (http:
//snpeff.sourceforge.net/SnpSift.html) based on (1) quality
(GATKfilterpass,quality>30), (2)effectonthecodingsequence
of a protein-coding gene (exonic nonsynonymous single-
nucleotide variant or splice variant), (3) frequency in public
databases of no greater than 1% (Exome Variant Server [http:
//evs.gs.washington.edu/EVS/] and Exome Aggregation
Consortium [http://exac.broadinstitute.org/, https://www
.biorxiv.org/content/early/2016/05/10/030338]), and (4)
internal frequency (allele count ≤30; ie, ≤4.7%). IntersectBed
(http://bedtools.readthedocs.io/en/latest/) allowed filtering
variants affecting known CA or hereditary spastic paraplegia
genes, because both overlap clinically, based on curation of
PubMed performed in February 2015 and in-house lists (209
genes) (eTable 1 in the Supplement). Variants in other genes
were not examined.
Key Points
Questions Is exome-targeted capture sequencing able to detect
mutations in genes broadly linked to ataxia, and what is the
prevalence of suchmutations in a large cohort of undiagnosed
patients with various phenotypic presentations?
Findings This cohort study of 319 patients with undiagnosed
cerebellar ataxia used a sequencing approach that allowed the
identification of genetically relevant variants in known genes in 91
(28.5%). This approach had the highest success rate for patients
with spastic ataxia or a cerebellar ataxia with oculomotor
apraxia–like phenotype; SPG7, SACS, SETX, SYNE1, and CACNA1A
were themost frequently mutated genes.
Meaning Mutations were identified in a broad range of genes
implicated in ataxia and related neurologic diseases, even in
cohorts that underwent previous extensive screening.
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Variants Processing
Biallelic (homozygous or compound heterozygous) variants
were first sought because of the likelihood of AR inheritance.
Very rare (≤0.1% frequency in the aforementioned databases)
heterozygous variants were also considered in ADCA genes
(eTable 1 in the Supplement and Figure 1). The plausibility of
genotype-phenotypecorrelationswasevaluated for all flagged
variants.
Sanger sequencing was performed if (1) the variant read
depth was below 10 × , (2) informative family members were
available for segregation (other affected members [n = 13] or
healthy relatives without biallelic mutations [n = 6]), or (3) it
allowed determining the cis- or trans-localization of com-
pound heterozygous variants (n = 7). All Sanger resequenced
variants and segregation results are reported in eTable 2 in the
Supplement.
Results
The 319 included patients had equal sex distribution (160 fe-
male [50.2%] and 159 male [49.8%] patients). Mean (SD) age
Table. Clinical Subgroups Among the Cohort
Clinical Group
No. of
Index
Patients
No. (%) of Patients
Age at Onset
<25 y
Age at Onset
>40 y Consanguinity
Very Probable
or Definite
Diagnosis
Very Probable
or Definite
Diagnosis
When Age at
Onset <25 y
Very Probable
or Definite
Diagnosis
When Age at
Onset >40 y
Possible
Diagnosis
AOA-like phenotype
(increased α-fetoprotein
level, low albumin level,
ocular apraxia)
17 15 (88.2) 1 (5.9) 7 (41.2) 6 (35.3) 6 (35.3) 0 2 (11.8)
Late complex
(MSA-like, parkinsonism,
not pyramidal)
30 0 20 (66.7) 7 (23.3) 3 (10.0) 0 0 1 (3.3)
Metabolic (mitochondrial
features, white matter
changes)
70 45 (64.3) 6 (8.6) 24 (34.3) 16 (22.9) 10 (14.3) 0 2 (2.9)
Pure (only cerebellar signs,
slow progression)
62 20 (32.3) 13 (21.0) 19 (30.6) 9 (14.5) 5 (8.1) 0 6 (9.7)
Sensory ataxia
(FRDA/PolG-like)
19 9 (47.4) 8 (42.1) 8 (42.1) 2 (10.5) 2 (10.5) 0 2 (10.5)
Spastic ataxia (cerebellar
and pyramidal signs)
100 42 (42.0) 15 (15.0) 36 (36.0) 35 (35.0) 18 (18.0) 4 (4.0) 6 (6.0)
Alla 298 131 (44.0) 63 (21.1) 101 (33.9) 72 (22.6)b 41 (31.3) 4 (6.4) 19 (5.9)
Abbreviations: AOA, cerebellar ataxia with oculomotor apraxia;
FRDA, Friedreich ataxia; MSA, multisystemic atrophy; PolG, polymerase gamma.
a Includes the 298 patients for whom complete clinical information was
available.
b Includes 1 patient with known SPG7mutations lacking sufficient clinical
information for classification.
Figure 1. General Study Results
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Variants were sorted based on classic criteria (detailed in the Variant Analysis
subsection of the Results section), then analyzed assuming an autosomal
recessive (AR) transmissionmode (including homozygous and heterozygous
compound variants), which allowed identifying possibly to definitely causative
variants in 74 patients (23.2%). Combining this analysis with one based on
presumed autosomal dominant (AD) transmission (including heterozygous
varients and a frequency0.1%) improved this number to 91 patients (28.5%)
for AD and AR inheritancemodes, with 10 additional patients carrying very
probable to definite pathogenic mutations. VUS indicates variant of unknown
significance.
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atonsetwas27.9 (18.6)years; theageatonsetwasyounger than
25 years for 131 of 298 patients (44.0%) with complete clini-
cal data.
Sequencing
Approximately8gigabasesofalignablesequencedataweregen-
eratedper sample.Onaverage,95%ofexomecapturebaitshad
at least a 10 × depth and 70% at least a 30 × depth. A total of
488393 single-nucleotide polymorphisms and 69480 indels
were included.Wedeliberately retainedpatientswith lowcov-
erage to avoid distorting the percentage of positive findings.
Variant Analysis
The aforementioned analysis (Figure 1) provided 0 to 4 (AR)
or 0 to 2 (AD) candidate genes per patient.Wedefined the fol-
lowing4pathogenicity groups: (1) probable or definitive caus-
ative variant(s), including a knownor a recurrent variant, 3 or
4 concordant pathogenicity predictions by sorting intolerant
from tolerant (SIFT), polymorphism phenotyping 2 (Poly-
Phen2)HumDiv, LRT, andMutation Taster andGenomic Evo-
lutionary Rate Profiling (GERP++) score of greater than 3 and
plausible genotype-phenotypeassociation, or compatiblebio-
markervalues (suchashexaminidase levels); (2)possibly caus-
ative variant(s), includingmost of the above but at least 1 cri-
terionmissing, or a slightlydiscordantphenotype for the gene
spectrum; (3) variant(s) of clinically unknown significance
(VUS); and (4) no diagnosis, including no variant in a known
gene or a variant in known genes without convincing genet-
ics arguments to match the clinical phenotype or the ad-
equate inheritance mode.
Weobtainedveryprobableordefinitediagnoses for 72pa-
tients (22.6%; including 62 with AR and 10 with AD inheri-
tance) (Figure 1).We identifiedpossibly causative variants for
an additional 19 patients (6.0%; 12 with AR and 7 with AD in-
heritance). Themost frequently encountered recessivemuta-
tions were in SPG7 (n = 14), followed by SACS (n = 8), SETX
(n = 7), and SYNE1 (OMIM 608441) (n = 6) (Figure 2). Domi-
nantmutationsweremost numerous inCACNA1A (n = 6), fol-
lowed by PRKCG (OMIM 176980) (n = 3). Possible to definite
variants are listed in eTable 2 in the Supplement, with argu-
ments for their classification; VUS are available in eTable 3 in
the Supplement.
Diagnostic Yield per Clinical Group
The best diagnositic yieldswere found for AOA-like presenta-
tionswith positive biological biomarkers (6 of 17 [35.3%]) and
Figure 2. Number of Possible to Definite Diagnoses per Gene and Disease Group
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The left part of the Figure plots the number of patients identified with possible
to definite mutations for each gene listed. The right part shows the repartition
of these patients among the 6 disease subgroups. Disease groups are described
in the Patient Recruitment and Clinical Evaluation subsection of theMethods
section. AD indicates autosomal dominant; AR, autosomal recessive;
AOA, cerebellar ataxia with oculomotor apraxia.
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spastic ataxias (35 of 100 [35.0%]) as very probable or defi-
nite and 2 of 17 (11.8%) and6of 100 (6%), respectively, as pos-
sible (Table). Patientswith late complexCAthenwere the least
frequently diagnosed, with 3 of 30 (10.0%) as very probable
or definite and 1 of 30 (3.3%) as possible. Early disease onset
and consanguinity were associatedwith better chances of di-
agnoses (41 of 131 [31.3%] with very probable or definite with
onsetbefore25yearsvs4of63 [6.4%]after40years; 31 [30.7%]
with consanguinity vs 41 [18.8%] without).
The predefined clinical group was generally concordant
with the genetic diagnosis (Figure 2), with some exceptions.
Onepatientwith anAOA-likepresentation (AAR-211-3) had el-
evated α-fetoprotein levels, no variant in theAPTX gene, and
pathogenic mutations in the ANO10 gene (NM_018075.4:
c.132dupA:p.D45fs;c.1537T>C:p.C513R). PatientswithANO10
mutations usually develop cerebellar symptoms in adult-
hood(aged17-43years19),whereaspatientswithAOAshowear-
lier onset. Onset at 24 years of age in this patient was coher-
ent with ANO10 mutations. We classified the diagnosis as
possible because the clinical presentation was slightly un-
usual.Otherpatientswithbiallelic loss-of-functionANO10vari-
ants had classic spastic ataxia.
One patient (AFT-76-10) with epilepsy, thus classified in
the metabolic group, carried a CACNA1A frameshift (NM
_001127222.1:c.2493dupC:p.N832fs). Autosomal recessive in-
heritancewas first assumedbecauseofaconsanguineouspedi-
gree, but a dominant history later appeared,with ataxic signs
in the daughter of a cousin, for whom no DNA was available
for testing.
One patient with spastic ataxia (SAL-399-573) harboured
2 nonsense variants in SYNE1 (NM_182961.3:c.14273T>G:
p.L4758X;c.23346G>A:p.W7782X). Pyramidal signswere clas-
sically limited in the SYNE1 spectrum, but recent results have
established that spasticity is part of the phenotype.20
Reports of Peculiar Phenotypes
We classif ied a previously reported PDYN variant
(NM_001190898.2:c.616C>T:p.R206C21) as VUS. Its fre-
quency in the ExomeAggregationConsortium (0.026%, or 16
heterozygous individuals), the lack of an effect on prodynor-
phin processing to dynorphin A and B,21 and the discordant
phenotypeof this Frenchpatient (AAR-287-4with childhood-
onset ataxia, intellectual disability, andbehavioral abnormali-
ties) relative to thepreviously reported late-onset spasticataxia
cast its pathogenicity in doubt.
We found a possibly causative KCND3 variant (NM
_004980.4:c.641A>G:p.K214R) inapatientwithanunusualepi-
sodic gait disorder. The onset of relapsing limb paraesthesia
at 30 years of age first evoked multiple sclerosis. Vertigo and
episodicoccurrencesofgaitdisorderappeared thereafterwith-
out interictalataxia. Increasedreflexes, theHoffmannsign,uni-
lateral extensor plantar reflexes, and saccadic ocular pursuit
were observed. Magnetic resonance imaging showed supe-
rior cerebellar vermis atrophy. The unaffected mother car-
ried thevariant, suggesting incompletepenetrance. This find-
ing might be in accordance with its prevalence in public
databases (28 of 119072 alleles; ie, 28 heterozygous among
59536 individuals [0.05%]).
One patient (AAR-180-11) harbored a previously
reported homozygous frameshift variant of ANO10
(NM_018075.4:c.132dupA:p.D45fs).19 This specific variant
was always found in compound heterozygosity with others
and assumed to be too severe when homozygous. The onset
at 22 years in this homozygous patient and a mild spastic
ataxic phenotype (stage 1 disability with no functional
handicap) after 5 years of disease evolution is in accordance
with previous reports for ANO10 showing it to not be more
severe.
Finally, 2 siblings (AAR-73-3 and AAR-73-4) with spastic
ataxia fromaconsanguineouspedigree carrieda causativeho-
mozygousnonsenseERCC5variant (NM_000123.3:c.3004C>T:
p.Q1002X).The indexpatient (AAR-73-4)presentedwith spas-
tic paraparesis, proximal and distal weakness, and severe
sensory-motor demyelinating neuropathy at 24 years of age.
Sheusedawalkingaidat48yearsofage,waswheelchairbound
at 52 years of age, and had limited upward gaze and cognitive
impairment at 54 years of age. The Scale for the Assessment
and Rating of Ataxia score (18 of 40 at 46 years of age and 29
of 40 at 54 years of age) denoted clear progressivity. Mag-
netic resonance imaging of the brain showed slight cerebellar
atrophy and white matter anomalies (Figure 3). Her brother
(AAR-73-3) started to show signs of the disease at 15 years of
age, used a walking aid at 39 years of age, andwas bedridden
and died at 51 years of age. The ERCC5 gene belongs to a DNA
repair pathway; biallelicmutationshavebeenassociatedwith
xeroderma pigmentosum, Cockayne syndrome, and com-
bined xeroderma pigmentosum–Cockayne syndrome
phenotypes.22,23 Major characteristics from classic xero-
derma pigmentosum–Cockayne syndrome presentations (in-
creasedphotosensitivity, skinpigmentationabnormalities, en-
ophthalmos, progressivemicrocephaly, deafness, or retinitis)
were absent. Our finding is nevertheless consistent with the
ataxic gait of some patients with ERCC5mutations.24
Discussion
Weused exome-targeted capture sequencing followedby tar-
geted analysis of genes broadly linked to CA to study 319 pa-
tients with undiagnosed CA, the largest such cohort to date,
to assess the possibility of detecting mutations with this ap-
proach and their prevalence. Previously reported cohorts in-
cluded nomore than 76 patients.9
Ourdiagnosticyieldwas22.6%(72of319patients),with5.9%
(19of319)possibleadditionaldiagnoses(Figure1).Thisratemight
be lower because our cohort, recruited through a specialized
university-basednetworkof referencecenters for rarediseases,
hasundergoneextensive screeningpreviously.However, these
findings are similar to those of previous reports using targeted
gene panels (18%8) or exome sequencing (21%-46%8-12,25) and
other mendelian diseases (34% diagnoses in heterogeneous
patients26; 33% in hereditary spastic paraplegia27).
The diagnostic yield was highly variable among clinical
subgroups, being the highest for AOA-like phenotypes and
spastic ataxias and the lowest for late-onset complex cases. It
was also lower in patients with onset after 40 years of age
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(6.4%), in accordance with other observations.8,25 This find-
ingmaybeexplainedby less extensiveknowledgeof genes im-
plicated in late-onset ataxias or by themore frequent involve-
ment of nongenetic causes.
In 9 cases, the diagnosis was established during the study
butnotconfirmed.Fivepatients carrieddisease-causing repeat
expansions,whichcannotbedetectedbyshort-readtechniques
owingtothelimitedreadlength.These5patients included1with
a heterozygousATXN7polyglutamine expansion, 1with a het-
erozygous and 1with ahomozygousATXN3polyglutamine ex-
pansion, and2withpathogenic expansions inFXN. In thispre-
dominantlyAR-assumedpopulation,CAGrepeatexpansions in
ATXN1,ATXN2,ATXN3,CACNA1A,ATXN7,TBP, andATN1were
soughtbasedonlyonsuggestive clinical elementsonexamina-
tion,aswereGAArepeats inFXN.Asixthpatientharbouredaho-
mozygous 31-kbdeletion inANO10 encompassing exon 12 that
wasnotdetectedbyourapproach.Mutations inNDRG1 (OMIM
605262)were reported inanotherpatientduring thestudypro-
cess.This gene,mostly implicated inCharcot-Marie-Toothdis-
ease type 4D, was not included in our list. Finally, 2 patients
flagged by quality check metrics were diagnosed with APTX-
linkedandSPG7-linkedCA,but lowglobal coverageprohibited
fromdetecting the variants.
Exome-targetedcapturesequencing iswidelyavailableand
has several advantages compared with other sequencing ap-
proaches. If targeted gene panel sequencing is a cost-
effective alternative to focus on many genes in 1 run, it re-
quires anadditional design stepand redesignasnewgenes are
linked to CA. Conversely, exome capture allows post hoc re-
analysis ofdata asother groups identifymutations innew(CA)
genes. For example, 2 patients not included in the claimeddi-
agnosedgroup carriedmutations inCAPN128 and2others car-
ried mutations in SLC25A46.29
This approach also allows a broader range of genes to be
tested. When AR inheritance is the prime hypothesis, genes
with AD-transmitted mutations might be overlooked. Even
without adominant transmissionhistory,ADanalysis yielded
a significant amount of additional diagnoses (Figure 1 and
Figure 2), including 3 in consanguineous pedigrees. Two di-
agnoses were pathogenic, including a previously reported
PRKCGmutation and a CACNA1A frameshift, which is classic
for this gene.30 Possible explanations include the de novo oc-
currence of the variant, incomplete penetrance, a censor ef-
fect owing to premature death, or paternity issues. Autoso-
mal dominant analysis significantly raised thenumber ofVUS
because missense heterozygous variations are difficult to in-
terpret. Our results confirm CACNA1A as a prominent gene in
CA, which we also confirmed in an independent AD cohort.31
We often did not have access to DNA from relatives because
patients were from an adult neurologic clinic and were en-
rolled during the course of several years. Access to DNA from
relatives would have allowed the detection of de novo vari-
ants or confirmation of the localization of heterozygous com-
pound mutations in trans. Whenever possible, sequencing a
trio might prove to be more efficacious.
Ingeneral, next-generationapproaches circumvent the is-
sue of gene prioritization based on phenotypic presump-
tions, with the limitation of the aforementioned expansions.
Thisnonsystematic, time-consuming, classic approachmissed
the diagnosis in the prescreened patients in the absence of
pathognomonic signs.Most genesmutated inour cohortwere
implicated in only 1 or 2 patients (Figure 2). Furthermore,
exome-targeted capture sequencing allows abroader rangeof
genes to be tested, including genes associated with neuro-
logic diseases but not typically with ataxia. We enlarged the
clinical spectrum linked to genes for which the phenotype is
notprimarilyCA, suchasERCC5,PLA2G6, orSPG7. Careful ex-
aminationof clinical records revealed suggestive signsof these
syndromes in most cases. However, they were not suffi-
ciently suggestive to have been evoked at first glance. More-
over, mutations in a given gene can lead to divergent pheno-
types spreadover several clinical groups (≤4 for SYNE1, SETX,
and ADCK3). Capturing the exomemakes it possible to avoid
prior assumptions about the causative gene.10
Figure 3. Magnetic Resonance Image of the Brain in a Patient
T1-weighted imageA Fluid-attenuated inversion recovery imageB
Awoman in her 40s harbored
homozygous nonsensemutations in
ERCC5 (p. Q1002X). After 22 years of
disease evolution, the sagittal section
of a T1-weighted image (A) showed
mild atrophy of the upper cerebellar
vermis (white arrowhead), and the
axial fluid-attenuated inversion
recovery section (B) showed slight
white matter blurring (black
arrowheads).
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Spastic paraplegia genes are themost frequent example of
phenotypebroadening,withmutationsinSPG7andSACSaswell
as CYP7B1, SPG11, and PLA2G6 (Figure 2 and eTable 2 in the
Supplement).SPG7mutationswere recently recognized tobea
major cause of CA32;most patients, however, develop pyrami-
dal signs alongwith disease progression. In our cohort, 9 of 14
patientswithSPG7mutationshadaspasticphenotype (64.3%)
and 2 of 14 had pyramidal signs, although theywere classified
asmetabolic.Sixof8patientswithSACSmutations (75.0%)pre-
sentedwithspasticataxia,and1presentedwithpyramidal signs
and demyelinating neuropathy. One patient harbouring possi-
blycausativevariantshada lessclassicphenotypeofperipheral
neuropathy,epilepsy,andmyoclonus.Testingforatraitbiomark-
er, suchasanalterationofmitochondrial networkmorphology
in fibroblasts,33might help to reach a definite conclusion.
Convincinggeneticdata, however, usually correlatedwith
a characteristic phenotype. In some cases, the clinical fea-
tures reinforced the genetic diagnostic presumption. We did
not use the clinicogenetic correlation as an exclusion crite-
rion when the variant was genetically convincing, as sug-
gested by others,9,34 althoughwe classified patientswith dis-
cordant clinical signs as possibly diagnosed, except for 1
CACNA1A frameshift. Instead, we used clinicogenetic corre-
lation to strenghten evidence of pathogenicity. Genotype-
phenotype correlations are highly challenged by next-
generation sequencing,7 but clinical presentation, including
neuroimaging findings, such as the degree of cerebellar atro-
phy or abnormal basal ganglia signal, should remain a promi-
nent criterion indeciphering thepathogenicity of a givenvari-
ant for a given patient.35
When available, trait biomarkers also aid the establish-
ment of the pathogenicity of variants, as shown by the well-
known example of elevated α-fetoprotein levels in ataxia-
telangiectasia linked to ATM mutations. Oxysterol levels in
patients harbouring CYP7B1 mutations are usually elevated,
as in 1 patient carrying a homozygous nonsense variant (NM
_004820.4:c.524G>A:p.W175X). Individualswithmutations in
HEXA have low levels of hexaminidase A, as in 1 patient with
an AOA-like presentation and a homozygousmissensemuta-
tion (NM_000520.5:c.1511G>A:p.R504H) who was consid-
ered to be diagnosed despite discordant in silico pathogenic-
ityestimates.Anotherpatientwitha spasticphenotypecarried
2 missense variants (NM_000520.5:c.739C>T:p.R247W;
c.1033G>A:p.G345S) forwhichpathogenicity couldnotbecon-
firmedbyhexaminidasedosage and thatwe thus labeledpos-
siblypathogenic.TTPAmutations areusually accompaniedby
vitamin E deficiency. This was confirmed in one patient with
a homozygous frameshift (NM_000370.3:c.744delA:
p.E248fs)butnot inanotherwithcompoundheterozygousmis-
sense variants and a slightly divergent clinical profile (NM
_000370.3:c.265C>T:p.P89S;c.515C>G:p.T172S). The
characteristicmagnetic resonance imagingsignofapallidalT2-
weightedhyposignalwas observedon reexamination for 1 pa-
tient with PLA2G6 mutations (NM_003560.3:c.1903C>T:
p.R635X;c.T2411C:p.L804P),allowingus toclassify thevariants
as probably causative. Trait biomarkers, although not obliga-
tory, are invaluable diagnostic tools when present. In the ab-
sence of such biomarkers, it is often difficult to reach a defi-
nite conclusion, as for the 49VUS thatwe identified (eTable 3
in the Supplement).
Limitations
Themajor limitations of our approach rely in the fact that we
missedsomevariants (ie, trinucleotide repeatsexpansions that
cannot be detected by short-read sequencing and variants in
genes not included in our design). The first fallback is inher-
ent to the sequencing technique and can only be avoided by
choosing another sequencing approach. The second limita-
tion is a bioinformatics issue that can be solved by updating
the gene list. Compared with the panel techniques, the cov-
erage of all human genesmight also not be optimized and the
sequencing might be more expensive.
Conclusions
We aimed at assessing the efficacy of exome-targeted cap-
ture sequencing followed by analysis of genes known to be
broadly linked to ataxia to identify mutations in undiag-
nosed patients. This technique is not optimized for sequenc-
ing a specific subset of genes, contrary to focused resequenc-
ing arrays, but is commonly available and allows the post hoc
reanalysis of data as new causative genes are identified and
the inclusion of a broader range of genes in the study design.
We focused on a set of 209 genes, which allowed 30% of ad-
ditional diagnoses in our otherwise extensively prescreened
cohort. Our results confirm the genetic heterogeneity of CA,
withmanygenesstill todiscover inongoingworkwiththis large
cohort. Our strategy may be efficacious for obtaining results
for known genes and for future development.
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